{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:40:13Z","timestamp":1776087613215,"version":"3.50.1"},"reference-count":68,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Vitiligo is a chronic autoimmune depigmenting disorder characterized by the selective destruction of epidermal melanocytes. Proinflammatory and anti-inflammatory cytokines, such as interferon \u03b3 (IFN-\u03b3) and interleukin 10 (IL-10), play a pivotal role in its pathogenesis. Quantifying these cytokines and assessing their ratio may aid in disease prognosis and therapeutic monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To evaluate the association between the IFN-\u03b3:IL-10 ratio and the clinical as well as histopathologic characteristics of stable and unstable vitiligo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A hospital-based prospective case-control study was conducted during 1 year (2023\u20132024) on 70 patients with active vitiligo and 30 healthy controls. Serum levels of IFN-\u03b3 and IL-10 were quantified, and their correlations with clinical severity, disease stability, and histopathologic grading were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>\n                      Unstable vitiligo cases demonstrated significantly higher histopathologic scores (\u22653 in 39.62% versus 0% in stable cases,\n                      <jats:italic>P<\/jats:italic>\n                      = .002). IFN-\u03b3 levels were markedly elevated in unstable vitiligo (11.9 \u00b1 2.56 versus 10.58 \u00b1 1.04 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      = .003) and in patients with a histopathologic score of 3 or higher (13.35 \u00b1 3.21 versus 10.84 \u00b1 1.34 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      = .002). The IFN-\u03b3:IL-10 ratio was also significantly higher in these groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Differentiating stable from unstable vitiligo is essential for optimal disease management. Cytokine profiling, particularly IFN-\u03b3 and IL-10 levels, offers a minimally invasive biomarker for assessing disease activity and monitoring therapeutic response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2025-0099-oa","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:02:01Z","timestamp":1749499321000},"page":"1101-1108","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Interferon \u03b3 to Interleukin 10 Ratio as a Biomarker for Stability and Severity in Vitiligo: A Clinical and Histopathologic Correlation"],"prefix":"10.5858","volume":"149","author":[{"given":"Geet","family":"Bhuyan","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Lakhimpur Medical College and Hospital, Assam, India (Bhuyan)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minakshi","family":"Narah","sequence":"additional","affiliation":[{"name":"the Departments of Dermatology (Narah) and Pathology (Khound, Dutta), Jorhat Medical College and Hospital, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajashree","family":"Khound","sequence":"additional","affiliation":[{"name":"the Departments of Dermatology (Narah) and Pathology (Khound, Dutta), Jorhat Medical College and Hospital, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiba","family":"Dutta","sequence":"additional","affiliation":[{"name":"the Departments of Dermatology (Narah) and Pathology (Khound, Dutta), Jorhat Medical College and Hospital, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"issue":"9988","key":"i1543-2165-149-12-1101-b01","series-title":"Lancet","first-page":"74","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","unstructured":"Ezzedine K,\nEleftheriadou V,\nWhitton M,\nvan Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384."},{"issue":"3","key":"i1543-2165-149-12-1101-b02","series-title":"Pigment Cell Melanoma Res","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","unstructured":"Ezzedine K,\nLim HW,\nSuzuki T, et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1\u2013E13."},{"issue":"8","key":"i1543-2165-149-12-1101-b03","series-title":"Exp Dermatol","first-page":"759","article-title":"Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins","volume":"29","author":"Giri","year":"2020","unstructured":"Giri PS,\nDwivedi M,\nBegum R. Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp Dermatol. 2020;29(8):759\u2013775."},{"issue":"3","key":"i1543-2165-149-12-1101-b04","series-title":"Cosmetics","first-page":"84","article-title":"Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact","volume":"10","author":"L-smadi","year":"2023","unstructured":"L-smadi K,\nImran M,\nLeite-Silva VR,\nMohammed Y. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics. 2023;10(3):84"},{"issue":"2","key":"i1543-2165-149-12-1101-b05","series-title":"Arch Dermatol Res","first-page":"123","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","unstructured":"Gholijani N,\nYazdani MR,\nDastgheib L. Predominant role of innate pro-inflammatory cytokines in vitiligo disease. Arch Dermatol Res. 2020;312(2):123\u2013131."},{"key":"i1543-2165-149-12-1101-b06","series-title":"Clin Chim Acta","first-page":"27","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2202","unstructured":"Tembhre MK,\nSharma VK,\nSharma A,\nChattopadhyay P,\nGupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta. 2202;424:27\u201332."},{"issue":"3","key":"i1543-2165-149-12-1101-b07","series-title":"J Dermatol Sci","first-page":"78","article-title":"Targeting the elevated IFN-\u03b3 in vitiligo patients by human anti-IFN-\u03b3 monoclonal antibody hampers direct cytotoxicity in melanocyte","volume":"110","author":"Ng","year":"2023","unstructured":"Ng CY,\nChan YP,\nChiu YC, et al. Targeting the elevated IFN-\u03b3 in vitiligo patients by human anti-IFN-\u03b3 monoclonal antibody hampers direct cytotoxicity in melanocyte. J Dermatol Sci. 2023;110(3):78\u201388."},{"issue":"1","key":"i1543-2165-149-12-1101-b08","series-title":"J Cutan Aesthet Surg","first-page":"38","article-title":"Stability in vitiligo? What\u2019s that","volume":"2","author":"Lahiri","year":"2009","unstructured":"Lahiri K. Stability in vitiligo? What\u2019s that? J Cutan Aesthet Surg. 2009;2(1):38\u201340."},{"issue":"suppl","key":"i1543-2165-149-12-1101-b09","series-title":"Indian J Dermatol Venereol Leprol","first-page":"S37","article-title":"Standard guidelines of care for vitiligo surgery","volume":"74","author":"Parsad","year":"2008","unstructured":"Parsad D,\nGupta S; IADVL Dermatosurgery Task Force. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol. 2008;74(suppl):S37\u2013S45."},{"issue":"5","key":"i1543-2165-149-12-1101-b10","series-title":"J Eur Acad Dermatol Venereol","first-page":"518","article-title":"Surgical treatment of vitiligo: why, when and how","volume":"17","author":"Falabella","year":"2003","unstructured":"Falabella R. Surgical treatment of vitiligo: why, when and how. J Eur Acad Dermatol Venereol. 2003;17(5):518\u2013520."},{"issue":"8","key":"i1543-2165-149-12-1101-b11","series-title":"Am J Dermatopathol","first-page":"608","article-title":"Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases","volume":"38","author":"Yadav","year":"2016","unstructured":"Yadav AK,\nSingh P,\nKhunger N. Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases. Am J Dermatopathol. 2016;38(8):608\u2013613."},{"issue":"2","key":"i1543-2165-149-12-1101-b12","series-title":"Br J Dermatol","first-page":"265","article-title":"Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo","volume":"168","author":"Benzekri","year":"2013","unstructured":"Benzekri L,\nGauthier Y,\nHamada S,\nHassam B. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol. 2013;168(2):265\u2013271."},{"issue":"4","key":"i1543-2165-149-12-1101-b13","series-title":"Dermatol Pract Concept","first-page":"e2023197","article-title":"Dermatoscopic patterns in vitiligo","volume":"13","author":"God\u00ednez-Chaparro","year":"2023","unstructured":"God\u00ednez-Chaparro JA,\nRold\u00e1n-Mar\u00edn R,\nVidaurri-de la Cruz H,\nSoto-Mota LA,\nF\u00e9rez K. Dermatoscopic patterns in vitiligo. Dermatol Pract Concept. 2023;13(4):e2023197."},{"issue":"2","key":"i1543-2165-149-12-1101-b14","series-title":"J Cutan Aesthet Surg","first-page":"75","article-title":"Stability in vitiligo: is there a perfect way to predict it","volume":"6","author":"Sahni","year":"2013","unstructured":"Sahni K,\nParsad D. Stability in vitiligo: is there a perfect way to predict it? J Cutan Aesthet Surg. 2013;6(2):75\u201382."},{"issue":"7","key":"i1543-2165-149-12-1101-b15","series-title":"Biomedicines","first-page":"1639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da","year":"2022","unstructured":"Hla\u010da N,\n\u017dagar T,\nKa\u0161telan M,\nBrajac I,\nPrpi\u0107-Massari L. Current concepts of vitiligo immunopathogenesis. Biomedicines. 2022;10(7):1639."},{"key":"i1543-2165-149-12-1101-b16","series-title":"Front Immunol","first-page":"613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface","year":"2021","unstructured":"Boniface K,\nPasseron T,\nSeneschal J,\nTulic MK. Targeting innate immunity to combat cutaneous stress: the vitiligo perspective. Front Immunol. 2021;12:613056."},{"issue":"2","key":"i1543-2165-149-12-1101-b17","series-title":"in J Allergy Clin Immunol. 2020;146(4):924]. J Allergy Clin Immunol","first-page":"632","article-title":"Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo [published correction appears","volume":"145","author":"Li","year":"2020","unstructured":"Li S,\nKang P,\nZhang W, et al. Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo [published correction appears in J Allergy Clin Immunol. 2020;146(4):924]. J Allergy Clin Immunol. 2020;145(2):632\u2013645."},{"issue":"2","key":"i1543-2165-149-12-1101-b18","series-title":"J Leukoc Biol","first-page":"163","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","unstructured":"Schroder K,\nHertzog PJ,\nRavasi T,\nHume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163\u2013189."},{"issue":"4","key":"i1543-2165-149-12-1101-b19","series-title":"Eur J Immunol","first-page":"e2250281","article-title":"The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","unstructured":"Liu H,\nWang Y,\nLe Q,\nTong J,\nWang H. The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54(4):e2250281."},{"issue":"6","key":"i1543-2165-149-12-1101-b20","series-title":"Acta Derm Venereol","first-page":"643","article-title":"IFN-\u03b3 in vitiligo, is it the fuel or the fire","volume":"95","author":"Harris","year":"2015","unstructured":"Harris JE. IFN-\u03b3 in vitiligo, is it the fuel or the fire? Acta Derm Venereol. 2015;95(6):643\u2013644."},{"key":"i1543-2165-149-12-1101-b21","series-title":"Front Immunol","first-page":"932265","article-title":"From IL-17 to IFN-\u03b3 in inflammatory skin disorders: is transdifferentiation a potential treatment target","volume":"13","author":"Belpaire","year":"2022","unstructured":"Belpaire A,\nvan Geel N,\nSpeeckaert R. From IL-17 to IFN-\u03b3 in inflammatory skin disorders: is transdifferentiation a potential treatment target? Front Immunol. 2022;13:932265."},{"issue":"6","key":"i1543-2165-149-12-1101-b22","series-title":"Dermatol Ther (Heidelb)","first-page":"1185","article-title":"Vitiligo, from physiopathology to emerging treatments: a review","volume":"10","author":"Migayron","year":"2020","unstructured":"Migayron L,\nBoniface K,\nSeneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb). 2020;10(6):1185\u20131198."},{"issue":"2","key":"i1543-2165-149-12-1101-b23","series-title":"J Cutan Med Surg","first-page":"157","article-title":"Cutaneous JAK expression in vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","unstructured":"Abdel Motaleb AA,\nTawfik YM,\nEl-Mokhtar MA, et al. Cutaneous JAK expression in vitiligo. J Cutan Med Surg. 2021;25(2):157\u2013162."},{"key":"i1543-2165-149-12-1101-b24","series-title":"Front Immunol","first-page":"790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","unstructured":"Qi F,\nLiu F,\nGao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125."},{"issue":"4","key":"i1543-2165-149-12-1101-b25","series-title":"Chin Med J (Engl)","first-page":"502","article-title":"Clinical significance of Koebner\u2019s phenomenon in vitiligo: a hospital-based epidemiological investigation from China","volume":"136","author":"Zhang","year":"2023","unstructured":"Zhang Y,\nDing X,\nWang F,\nLi M,\nDu J. Clinical significance of Koebner\u2019s phenomenon in vitiligo: a hospital-based epidemiological investigation from China. Chin Med J (Engl). 2023;136(4):502\u2013504."},{"issue":"2","key":"i1543-2165-149-12-1101-b26","series-title":"Indian Dermatol Online J","first-page":"147","article-title":"Koebnerization and generalized spread of vitiligo following radiotherapy","volume":"4","author":"Sanghavi","year":"2013","unstructured":"Sanghavi SA,\nDongre AM,\nKhopkar US. Koebnerization and generalized spread of vitiligo following radiotherapy. Indian Dermatol Online J. 2013;4(2):147\u2013148."},{"issue":"1","key":"i1543-2165-149-12-1101-b27","series-title":"Curr Protoc Immunol","first-page":"e63","article-title":"Mouse model for human vitiligo","volume":"124","author":"Riding","year":"2019","unstructured":"Riding RL,\nRichmond JM,\nHarris JE. Mouse model for human vitiligo. Curr Protoc Immunol. 2019;124(1):e63."},{"issue":"12","key":"i1543-2165-149-12-1101-b28","series-title":"J Eur Acad Dermatol Venereol","first-page":"2097","article-title":"The role of interleukins in vitiligo: a systematic review","volume":"32","author":"Gomes","year":"2018","unstructured":"Gomes IA,\nde Carvalho FO,\nde Menezes AF, et al. The role of interleukins in vitiligo: a systematic review. J Eur Acad Dermatol Venereol. 2018;32(12):2097\u20132111."},{"key":"i1543-2165-149-12-1101-b29","series-title":"Autoimmune Dis","first-page":"423490","article-title":"Association of IFN-\u03b3\u2009:\u2009IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis","volume":"2015","author":"Ala","year":"2015","unstructured":"Ala Y,\nPasha MK,\nRao RN,\nKomaravalli PL,\nJahan P. Association of IFN-\u03b3\u2009:\u2009IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis. Autoimmune Dis. 2015;2015:423490."},{"issue":"4","key":"i1543-2165-149-12-1101-b30","series-title":"Biochem Cell Biol","first-page":"474","article-title":"Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo","volume":"95","author":"Karam","year":"2017","unstructured":"Karam RA,\nZidan HE,\nKhater MH. Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo. Biochem Cell Biol. 2017;95(4):474\u2013481."},{"issue":"1","key":"i1543-2165-149-12-1101-b31","series-title":"J Am Acad Dermatol","first-page":"52","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes","year":"2004","unstructured":"Grimes PE,\nMorris R,\nAvaniss-Aghajani E,\nSoriano T,\nMeraz M,\nMetzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51(1):52\u201361."},{"issue":"2","key":"i1543-2165-149-12-1101-b32","series-title":"Intervirology","first-page":"106","article-title":"High IFN-\u03b3\/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis development","volume":"58","author":"Esp\u00edndola","year":"2015","unstructured":"Esp\u00edndola OM,\nOliveira LC,\nFerreira PM,\nLeite AC,\nLima MA,\nAndrada-Serpa MJ. High IFN-\u03b3\/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis development. Intervirology. 2015;58(2):106\u2013114."},{"issue":"1","key":"i1543-2165-149-12-1101-b33","series-title":"Sci Rep","first-page":"17626","article-title":"Baseline IFN-\u03b3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients","volume":"10","author":"Giunta","year":"2020","unstructured":"Giunta EF,\nBarra G,\nDe Falco V, et al. Baseline IFN-\u03b3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci Rep. 2020;10(1):17626."},{"key":"i1543-2165-149-12-1101-b34","series-title":"Front Immunol","first-page":"607217","article-title":"Use of IFN\u03b3\/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock","volume":"12","author":"K\u00f6nig","year":"2021","unstructured":"K\u00f6nig R,\nKolte A,\nAhlers O, et al. Use of IFN\u03b3\/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock. Front Immunol. 2021;12:607217."},{"issue":"9988","key":"i1543-2165-149-12-1101-b01","series-title":"Lancet","first-page":"74","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","unstructured":"Ezzedine K,\nEleftheriadou V,\nWhitton M,\nvan Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384."},{"issue":"3","key":"i1543-2165-149-12-1101-b02","series-title":"Pigment Cell Melanoma Res","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","unstructured":"Ezzedine K,\nLim HW,\nSuzuki T, et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1\u2013E13."},{"issue":"8","key":"i1543-2165-149-12-1101-b03","series-title":"Exp Dermatol","first-page":"759","article-title":"Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins","volume":"29","author":"Giri","year":"2020","unstructured":"Giri PS,\nDwivedi M,\nBegum R. Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp Dermatol. 2020;29(8):759\u2013775."},{"issue":"3","key":"i1543-2165-149-12-1101-b04","series-title":"Cosmetics","first-page":"84","article-title":"Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact","volume":"10","author":"L-smadi","year":"2023","unstructured":"L-smadi K,\nImran M,\nLeite-Silva VR,\nMohammed Y. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics. 2023;10(3):84"},{"issue":"2","key":"i1543-2165-149-12-1101-b05","series-title":"Arch Dermatol Res","first-page":"123","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","unstructured":"Gholijani N,\nYazdani MR,\nDastgheib L. Predominant role of innate pro-inflammatory cytokines in vitiligo disease. Arch Dermatol Res. 2020;312(2):123\u2013131."},{"key":"i1543-2165-149-12-1101-b06","series-title":"Clin Chim Acta","first-page":"27","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2202","unstructured":"Tembhre MK,\nSharma VK,\nSharma A,\nChattopadhyay P,\nGupta S. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta. 2202;424:27\u201332."},{"issue":"3","key":"i1543-2165-149-12-1101-b07","series-title":"J Dermatol Sci","first-page":"78","article-title":"Targeting the elevated IFN-\u03b3 in vitiligo patients by human anti-IFN-\u03b3 monoclonal antibody hampers direct cytotoxicity in melanocyte","volume":"110","author":"Ng","year":"2023","unstructured":"Ng CY,\nChan YP,\nChiu YC, et al. Targeting the elevated IFN-\u03b3 in vitiligo patients by human anti-IFN-\u03b3 monoclonal antibody hampers direct cytotoxicity in melanocyte. J Dermatol Sci. 2023;110(3):78\u201388."},{"issue":"1","key":"i1543-2165-149-12-1101-b08","series-title":"J Cutan Aesthet Surg","first-page":"38","article-title":"Stability in vitiligo? What\u2019s that","volume":"2","author":"Lahiri","year":"2009","unstructured":"Lahiri K. Stability in vitiligo? What\u2019s that? J Cutan Aesthet Surg. 2009;2(1):38\u201340."},{"issue":"suppl","key":"i1543-2165-149-12-1101-b09","series-title":"Indian J Dermatol Venereol Leprol","first-page":"S37","article-title":"Standard guidelines of care for vitiligo surgery","volume":"74","author":"Parsad","year":"2008","unstructured":"Parsad D,\nGupta S; IADVL Dermatosurgery Task Force. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol. 2008;74(suppl):S37\u2013S45."},{"issue":"5","key":"i1543-2165-149-12-1101-b10","series-title":"J Eur Acad Dermatol Venereol","first-page":"518","article-title":"Surgical treatment of vitiligo: why, when and how","volume":"17","author":"Falabella","year":"2003","unstructured":"Falabella R. Surgical treatment of vitiligo: why, when and how. J Eur Acad Dermatol Venereol. 2003;17(5):518\u2013520."},{"issue":"8","key":"i1543-2165-149-12-1101-b11","series-title":"Am J Dermatopathol","first-page":"608","article-title":"Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases","volume":"38","author":"Yadav","year":"2016","unstructured":"Yadav AK,\nSingh P,\nKhunger N. Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases. Am J Dermatopathol. 2016;38(8):608\u2013613."},{"issue":"2","key":"i1543-2165-149-12-1101-b12","series-title":"Br J Dermatol","first-page":"265","article-title":"Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo","volume":"168","author":"Benzekri","year":"2013","unstructured":"Benzekri L,\nGauthier Y,\nHamada S,\nHassam B. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol. 2013;168(2):265\u2013271."},{"issue":"4","key":"i1543-2165-149-12-1101-b13","series-title":"Dermatol Pract Concept","first-page":"e2023197","article-title":"Dermatoscopic patterns in vitiligo","volume":"13","author":"God\u00ednez-Chaparro","year":"2023","unstructured":"God\u00ednez-Chaparro JA,\nRold\u00e1n-Mar\u00edn R,\nVidaurri-de la Cruz H,\nSoto-Mota LA,\nF\u00e9rez K. Dermatoscopic patterns in vitiligo. Dermatol Pract Concept. 2023;13(4):e2023197."},{"issue":"2","key":"i1543-2165-149-12-1101-b14","series-title":"J Cutan Aesthet Surg","first-page":"75","article-title":"Stability in vitiligo: is there a perfect way to predict it","volume":"6","author":"Sahni","year":"2013","unstructured":"Sahni K,\nParsad D. Stability in vitiligo: is there a perfect way to predict it? J Cutan Aesthet Surg. 2013;6(2):75\u201382."},{"issue":"7","key":"i1543-2165-149-12-1101-b15","series-title":"Biomedicines","first-page":"1639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da","year":"2022","unstructured":"Hla\u010da N,\n\u017dagar T,\nKa\u0161telan M,\nBrajac I,\nPrpi\u0107-Massari L. Current concepts of vitiligo immunopathogenesis. Biomedicines. 2022;10(7):1639."},{"key":"i1543-2165-149-12-1101-b16","series-title":"Front Immunol","first-page":"613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface","year":"2021","unstructured":"Boniface K,\nPasseron T,\nSeneschal J,\nTulic MK. Targeting innate immunity to combat cutaneous stress: the vitiligo perspective. Front Immunol. 2021;12:613056."},{"issue":"2","key":"i1543-2165-149-12-1101-b17","series-title":"in J Allergy Clin Immunol. 2020;146(4):924]. J Allergy Clin Immunol","first-page":"632","article-title":"Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo [published correction appears","volume":"145","author":"Li","year":"2020","unstructured":"Li S,\nKang P,\nZhang W, et al. Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo [published correction appears in J Allergy Clin Immunol. 2020;146(4):924]. J Allergy Clin Immunol. 2020;145(2):632\u2013645."},{"issue":"2","key":"i1543-2165-149-12-1101-b18","series-title":"J Leukoc Biol","first-page":"163","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","unstructured":"Schroder K,\nHertzog PJ,\nRavasi T,\nHume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163\u2013189."},{"issue":"4","key":"i1543-2165-149-12-1101-b19","series-title":"Eur J Immunol","first-page":"e2250281","article-title":"The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","unstructured":"Liu H,\nWang Y,\nLe Q,\nTong J,\nWang H. The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54(4):e2250281."},{"issue":"6","key":"i1543-2165-149-12-1101-b20","series-title":"Acta Derm Venereol","first-page":"643","article-title":"IFN-\u03b3 in vitiligo, is it the fuel or the fire","volume":"95","author":"Harris","year":"2015","unstructured":"Harris JE. IFN-\u03b3 in vitiligo, is it the fuel or the fire? Acta Derm Venereol. 2015;95(6):643\u2013644."},{"key":"i1543-2165-149-12-1101-b21","series-title":"Front Immunol","first-page":"932265","article-title":"From IL-17 to IFN-\u03b3 in inflammatory skin disorders: is transdifferentiation a potential treatment target","volume":"13","author":"Belpaire","year":"2022","unstructured":"Belpaire A,\nvan Geel N,\nSpeeckaert R. From IL-17 to IFN-\u03b3 in inflammatory skin disorders: is transdifferentiation a potential treatment target? Front Immunol. 2022;13:932265."},{"issue":"6","key":"i1543-2165-149-12-1101-b22","series-title":"Dermatol Ther (Heidelb)","first-page":"1185","article-title":"Vitiligo, from physiopathology to emerging treatments: a review","volume":"10","author":"Migayron","year":"2020","unstructured":"Migayron L,\nBoniface K,\nSeneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb). 2020;10(6):1185\u20131198."},{"issue":"2","key":"i1543-2165-149-12-1101-b23","series-title":"J Cutan Med Surg","first-page":"157","article-title":"Cutaneous JAK expression in vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","unstructured":"Abdel Motaleb AA,\nTawfik YM,\nEl-Mokhtar MA, et al. Cutaneous JAK expression in vitiligo. J Cutan Med Surg. 2021;25(2):157\u2013162."},{"key":"i1543-2165-149-12-1101-b24","series-title":"Front Immunol","first-page":"790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","unstructured":"Qi F,\nLiu F,\nGao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12:790125."},{"issue":"4","key":"i1543-2165-149-12-1101-b25","series-title":"Chin Med J (Engl)","first-page":"502","article-title":"Clinical significance of Koebner\u2019s phenomenon in vitiligo: a hospital-based epidemiological investigation from China","volume":"136","author":"Zhang","year":"2023","unstructured":"Zhang Y,\nDing X,\nWang F,\nLi M,\nDu J. Clinical significance of Koebner\u2019s phenomenon in vitiligo: a hospital-based epidemiological investigation from China. Chin Med J (Engl). 2023;136(4):502\u2013504."},{"issue":"2","key":"i1543-2165-149-12-1101-b26","series-title":"Indian Dermatol Online J","first-page":"147","article-title":"Koebnerization and generalized spread of vitiligo following radiotherapy","volume":"4","author":"Sanghavi","year":"2013","unstructured":"Sanghavi SA,\nDongre AM,\nKhopkar US. Koebnerization and generalized spread of vitiligo following radiotherapy. Indian Dermatol Online J. 2013;4(2):147\u2013148."},{"issue":"1","key":"i1543-2165-149-12-1101-b27","series-title":"Curr Protoc Immunol","first-page":"e63","article-title":"Mouse model for human vitiligo","volume":"124","author":"Riding","year":"2019","unstructured":"Riding RL,\nRichmond JM,\nHarris JE. Mouse model for human vitiligo. Curr Protoc Immunol. 2019;124(1):e63."},{"issue":"12","key":"i1543-2165-149-12-1101-b28","series-title":"J Eur Acad Dermatol Venereol","first-page":"2097","article-title":"The role of interleukins in vitiligo: a systematic review","volume":"32","author":"Gomes","year":"2018","unstructured":"Gomes IA,\nde Carvalho FO,\nde Menezes AF, et al. The role of interleukins in vitiligo: a systematic review. J Eur Acad Dermatol Venereol. 2018;32(12):2097\u20132111."},{"key":"i1543-2165-149-12-1101-b29","series-title":"Autoimmune Dis","first-page":"423490","article-title":"Association of IFN-\u03b3\u2009:\u2009IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis","volume":"2015","author":"Ala","year":"2015","unstructured":"Ala Y,\nPasha MK,\nRao RN,\nKomaravalli PL,\nJahan P. Association of IFN-\u03b3\u2009:\u2009IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis. Autoimmune Dis. 2015;2015:423490."},{"issue":"4","key":"i1543-2165-149-12-1101-b30","series-title":"Biochem Cell Biol","first-page":"474","article-title":"Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo","volume":"95","author":"Karam","year":"2017","unstructured":"Karam RA,\nZidan HE,\nKhater MH. Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo. Biochem Cell Biol. 2017;95(4):474\u2013481."},{"issue":"1","key":"i1543-2165-149-12-1101-b31","series-title":"J Am Acad Dermatol","first-page":"52","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes","year":"2004","unstructured":"Grimes PE,\nMorris R,\nAvaniss-Aghajani E,\nSoriano T,\nMeraz M,\nMetzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51(1):52\u201361."},{"issue":"2","key":"i1543-2165-149-12-1101-b32","series-title":"Intervirology","first-page":"106","article-title":"High IFN-\u03b3\/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis development","volume":"58","author":"Esp\u00edndola","year":"2015","unstructured":"Esp\u00edndola OM,\nOliveira LC,\nFerreira PM,\nLeite AC,\nLima MA,\nAndrada-Serpa MJ. High IFN-\u03b3\/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis development. Intervirology. 2015;58(2):106\u2013114."},{"issue":"1","key":"i1543-2165-149-12-1101-b33","series-title":"Sci Rep","first-page":"17626","article-title":"Baseline IFN-\u03b3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients","volume":"10","author":"Giunta","year":"2020","unstructured":"Giunta EF,\nBarra G,\nDe Falco V, et al. Baseline IFN-\u03b3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci Rep. 2020;10(1):17626."},{"key":"i1543-2165-149-12-1101-b34","series-title":"Front Immunol","first-page":"607217","article-title":"Use of IFN\u03b3\/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock","volume":"12","author":"K\u00f6nig","year":"2021","unstructured":"K\u00f6nig R,\nKolte A,\nAhlers O, et al. Use of IFN\u03b3\/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock. Front Immunol. 2021;12:607217."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/12\/article-p1101.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/12\/1101\/3546345\/i1543-2165-149-12-1101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/12\/article-p1101.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/12\/article-p1101.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:14:29Z","timestamp":1770772469000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/12\/article-p1101.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2025-0099-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}